Drugs / SNDX-5613
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06226571 | May 2024 → Feb 2027 expected | acute myeloid leukemia | Syndax Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05360160 | Oct 2022 → Dec 2026 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03013998 | Nov 2016 → Dec 2028 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNDX-5613 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06226571 ↗ |
| Known as | revumenib | “treated with the menin inhibitor revumenib (NCT04065399 and NCT05360160).” PMID 41621809 ↗ Jan 2026 |
| Action | Inhibit | “Menin Inhibitor SNDX-5613” NCT05360160 ↗ |
| Route | Oral | “113 mg capsule or 110 mg tablet, oral, every 12 hours” NCT03013998 ↗ |